Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$8.15B |
$68.16
+0.90%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$7.98B |
$57.72
+23.36%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.91B |
$125.79
-1.90%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.86B |
$109.15
-0.65%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$7.53B |
$150.81
+0.30%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$7.27B |
$96.08
+0.07%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$7.13B |
$107.45
-1.20%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$6.94B |
$23.13
-1.07%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$6.85B |
$86.24
+3.99%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$6.45B |
$49.67
-1.13%
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$6.33B |
$218.97
+0.92%
|
|
GKOS
Glaukos Corporation
Glaukos markets ophthalmic drugs such as iDose TR and corneal health therapies (Photrexa, Epioxa), which are administered to treat eye conditions.
|
$6.04B |
$105.44
+1.04%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$6.04B |
$8.78
+1.27%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmic Drugs – direct development, licensing, and commercialization of eye-disease medications (e.g., MIEBO, XIIDRA).
|
$5.73B |
$16.22
+2.08%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.64B |
$40.38
+1.66%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.62B |
$118.20
+1.01%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.60B |
$90.08
+0.25%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.57B |
$219.76
+0.05%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$5.49B |
$11.40
+1.06%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$5.30B |
$33.41
+1.32%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$5.04B |
$27.50
-2.43%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$4.91B |
$29.72
+2.52%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$4.85B |
$67.81
+2.68%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$4.85B |
$53.30
-0.51%
|
|
WGS
GeneDx Holdings Corp.
Companion diagnostics partnerships leverage genomic data to identify patients for therapies.
|
$4.76B |
$165.51
-1.19%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.62B |
$33.47
+1.12%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.59B |
$8.02
+2.49%
|
|
ADMA
ADMA Biologics, Inc.
ADMA's core offerings are plasma-derived immunology therapeutics (immunoglobulins) used to treat immune deficiencies and related conditions.
|
$4.57B |
$19.14
-0.34%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.35B |
$54.34
-0.04%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$4.33B |
$46.05
+3.00%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.26B |
$100.24
+1.17%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.19B |
$70.27
-0.92%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.19B |
$24.82
+1.78%
|
|
SRRK
Scholar Rock Holding Corporation
Drug Delivery Platforms: platform-based approach enabling targeted modulation of growth factor signaling via antibodies.
|
$4.15B |
$43.14
+4.03%
|
Showing page 4 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
